ERBB2 and neoplasm: Given the known biological differences between receptor subtypes in breast cancer, and because therapeutic arm assignment in I-SPY 2 is driven by tumor HER2 status, we investigated differences in protein/phosphoprotein activation profiles by HR/HER2 and explored associations with pCR within each subtype across all arms.